Payment cuts and the future of fractional flow reserve

Fractional flow reserve (FFR) is an invasive pressure measurement performed during coronary angiography. While the angiogram shows the shape and apparent width of a narrowing, FFR estimates whether blood flow through that narrowing can meet the heart muscle’s demand. How payment cuts could reduce the use of fractional flow reserve during angiography is therefore a question about both clinical judgement and the practical economics of cardiac care.

For Australian patients, the United States Medicare fee debate needs careful translation. Australia’s Medicare is administered through the Medicare Benefits Schedule by Services Australia, while the American College of Cardiology’s Campaign for Patient Access was launched to oppose physician fee schedule cuts affecting cardiovascular care. The systems differ, but the shared concern is clear: when reimbursement falls faster than the resources needed to deliver a procedure, access can quietly narrow.

What FFR reveals inside a coronary artery

Angiography and FFR answer different questions. A tight-looking lesion may not limit flow, while a moderate narrowing may become important under the increased demand of exercise or stress. During FFR, a pressure wire measures pressure in the artery beyond the narrowing and compares it with pressure in the aorta while flow is increased, usually with a drug such as adenosine. A ratio at or below 0.80 has traditionally supported treating a suitable intermediate lesion; local protocols also consider other evidence.

The result can prevent a stent in a narrowing that looks concerning but does not impair physiology, or support intervention where anatomy alone is uncertain. FFR does not replace the angiogram. It adds haemodynamic information to the full clinical picture, including symptoms, exercise tolerance, imaging, diabetes, kidney function and the risk of using contrast.

Approach	What it establishes	Common role	Additional requirement	Payment sensitivity
Anatomy-only angiography	The apparent severity of a narrowing	Baseline assessment of coronary anatomy	Catheter laboratory, contrast and radiographic interpretation	Lower incremental exposure because it is the established workflow
FFR during angiography	Whether a suitable narrowing limits blood flow	Decisions about deferring or treating an intermediate lesion	Pressure wire, hyperaemic drug, extra procedure time and training	High when fixed costs and additional time are not adequately funded
iFR or a derived index	Pressure or calculated physiological significance	Selected intermediate-lesion decisions	Validated acquisition, computation or both	Potentially lower through shorter workflows, but still dependent on equipment and payment

No single cut-off is universal, and a technically poor tracing can make the result unreliable. Intracoronary nitroglycerin, severe disease, unusual anatomy, spasm and operator technique can affect interpretation. For an experienced team, however, the measurement can convert a subjective judgement about an intermediate lesion into a more defensible treatment decision.

Why a lower fee can alter medical decisions

A physician fee cut can affect behaviour without changing any clinical guideline. A fixed payment for an angiogram may not reflect the additional time, equipment and skill required for physiological assessment. Pressure wires have purchase and consumable costs, quality control takes staff time, and vasodilator medication plus careful interpretation lengthen the procedure. If those inputs are not funded separately, some practitioners may regard FFR as optional or reserve it for the hardest decisions.

The risk is indirect. Waiting lists can grow when complex cases are concentrated among a small number of trained operators, while departments with low procedure volumes may retire equipment that is not financially sustainable. Cuts may also encourage shorter consultations and weaker documentation. That does not prove clinically inappropriate care will follow; the effect depends on payment design, caseload and local capacity. Nevertheless, a programme may become less able to provide FFR when it is genuinely needed.

Reading a United States policy warning in Australia

The campaign’s American focus offers a useful warning, but it should not be applied as though the same rule governs Australia. In the United States, Medicare physician fee schedule changes affect professional payments, while facility payment is generally separate. In Australia, MBS item 38255 can encompass FFR performed with coronary angiography, including the pressure wire, angiogram and reporting. Public hospitals combine state and territory funding with Commonwealth outpatient arrangements; private hospitals negotiate insurer contracts and commonly use MBS-based schedules.

Australian providers still face narrow margins. Hospitals purchase devices and consumables in Australian dollars, and some pressure-wire products may be imported. Procurement decisions made by a hospital group in Melbourne, Sydney or Brisbane can determine whether a machine, wire and trained team are available across its sites. TGA approval is necessary for device marketing, but approval does not guarantee affordable supply, appropriate training or adequate payment for the time surrounding the measurement.

Local effects on patients and services

These funding choices become visible to patients in different ways. A person treated in a major public cardiology service may have FFR covered through public-hospital arrangements, yet still face travel from regional Victoria, the Northern Territory or western New South Wales. Private treatment in an outpatient catheter laboratory can involve an MBS rebate, insurer reimbursement and a gap fee. Clear estimates matter because the final private cost can depend on the insurer, facility and procedural complexity.

Access is also shaped by referral pathways. A regional patient referred to a cardiac centre in Adelaide, Perth or Darwin may already have travelled a long way before the question of FFR arises. Repeating an angiogram because physiological data were unavailable can expose the patient to another admission, fasting period and contrast load. Australian centres should preserve expertise in larger cities while building reliable telehealth links and regional referral protocols for people who cannot travel easily.

Why the clinical case remains strong

Clinical evidence for physiology-guided treatment remains strong even when budgets are under pressure. Randomised evidence associated with the FAME trials showed that physiology-guided treatment can reduce unnecessary stenting and identify lesions more likely to benefit from revascularisation. Used selectively, FFR can spare some patients a permanent implant, reduce procedure time and avoid later problems caused by treating a narrowing that does not limit flow. Those benefits align the interests of patients, clinicians and payers.

Pressure assessment is inappropriate for every angiogram. People with clear, severe disease may proceed on anatomy and clinical findings, while people without obstructive coronary disease may need another explanation for symptoms. Physiology-guided and anatomy-only decisions are complementary, not rival approaches. The strongest system uses FFR when uncertainty is likely to change management, supported by quality measures rather than targets that reward either constant use or blanket omission.

Safeguards for sustainable FFR programmes

Australian cardiac services can make responsible use more resilient by separating clinical decision-making from the financial mechanics of the catheter laboratory. The following safeguards support consistency and access:

Clinical and governance measures

• Record why physiology was or was not used for an intermediate lesion.
• Interpret pressure ratios alongside symptoms, imaging and angiographic findings.
• Maintain operator training, device familiarity and equipment quality checks.
• Audit appropriate use, patient outcomes and exposure to contrast.

Payment and service measures

• Review whether physician, facility and consumable costs are each funded fairly.
• Compare item and insurer rebates with the true time and resource cost.
• Protect advanced public-hospital capability during budget decisions.
• Support regional referral pathways instead of removing low-volume services.

Clinical leaders should review these measures with cardiologists, operators, nurses, procurement staff, private insurers and patient representatives. A price cut that removes a clinically valuable measurement may look efficient initially, but a later angiography, repeat admission or unnecessary stent can shift costs elsewhere. Sustainable reimbursement recognises the value of a correct decision, not simply the number of devices opened.

Keep physiology at the centre of cardiac care

Patients can help protect this decision-making process. When an angiogram is discussed, ask what the suspected narrowing is, whether it appears severe enough to limit blood flow, and whether pressure measurement could change stenting or avoid it. Request a plain-English explanation of the result and, for private care, a written estimate covering the specialist, facility, device and any likely out-of-pocket charge.

Clinicians, hospitals and policymakers can contribute evidence by documenting cases where fragmented funding made FFR unavailable, delayed, or available only in another centre. With consent, share those experiences with patient organisations, relevant professional colleges, state and territory health ministers, and policymakers reviewing cardiac access. Support payment arrangements that sustain trained teams and appropriate technology, preserving physiology-guided choices for patients who stand to benefit.